    Stephen Dilly | Aimmune Therapeutics, Inc. | ZoomInfo.com


Stephen George Dilly - Burlingame, CA | Intelius



























Sign In



We found Stephen George Dilly in Burlingame, CA


Stephen George Dilly

                                                                           Intelius found that Stephen George Dilly  is  a male between 50 and 60 years old from Burlingame, CA.  We have connected them to
                3 addresses,
                3 phones,
                and 4 relatives or associates.
         






Get Report Now

Age

Stephen George Dilly is in his 50s

Stephen Has Lived In

Burlingame, CA
San Francisco, CA

Stephen's Relatives

Edwina Mullens
Lynette Dilly
Frederick Dilly
Mullens Lynette







Stephen George Dilly



Zodiac SignTaurus



GenderMale



Professional Status
Avigen , Inc.



Get Report Now










Want to know more about Stephen? Get a comprehensive background report, find full phone numbers, and other contact information when available, all from billions of available public records.
            Continue below for more details about Stephen, or use our people search engine to find others.
Get Background Check on Stephen George Dilly
Get a Criminal Check on Stephen George Dilly
Get a Public Record Report on Stephen George Dilly
Get a People Search Report on Stephen George Dilly


Stephen George Dilly's Contact Information
Known Cities Lived In
Find out where Stephen George Dilly has lived as well as Stephen George Dilly's phone numbers and email addresses.




Stephen George Dilly Has Lived in 1 States
California Address for Stephen George Dilly


500 R******** D* 

Burlingame, CA


Has Lived In

Burlingame, CA
San Francisco, CA


Get Full Address Report










Phone Numbers Associated with Stephen George Dilly

(530) ***-**** - Burlingame, CA 
(650) ***-**** - Burlingame, CA 
(415) ***-**** - San Francisco, CA 


Get Full Phone Report



Email Addresses Associated with Stephen George Dilly

s****y@***.com


Get Email Report




Stephen George Dilly's Professional Information
Information regarding Stephen George Dilly's professional history.  Find out previous places Stephen George Dilly has worked as well as dates employed.
            The following data is not guaranteed for accuracy and should not be used for employment, insurance, credit eligibility, or for any other purpose covered under the Fair Credit Reporting Act.


Stephen George Dilly Has Worked at 2 Places
Company: Avigen , Inc.
               
Company: Physic Ventures
               Title: Strategic Advisor and Member of Advisory Board
Stephen George Dilly's Experience
Title: 
               Company: Avigen , Inc.
Job Details

Title: Strategic Advisor and Member of Advisory Board
               Company: Physic Ventures
Job Details
               Company Size: Less than $1 mil - Employee Range: Less than 25
Additional Professional Information on Stephen George Dilly

 See Stephen George Dilly's LinkedIn Profile



Stephen George Dilly's Social Network and Potential Email Matches
Find out potential social network profiles and potential email usernamed for Stephen George Dilly


Stephen George Dilly's known Social Networks And Potential Email Matches

Find all of Stephen George Dilly's Social Network Profiles

Get Full Report

Search Social Networks
Including Facebook, LinkedIn, MySpace, Google, Twitter, Yahoo, Jigsaw, ZoomInfo and more



Potential Email Matches
Stephen Dilly
Username Matches

                  StephenDilly
                  DillyStephen
                  Stephen.Dilly
                  Dilly.Stephen
                  Stephen_Dilly
                  Dilly_Stephen
                  Stephen-Dilly
                  Dilly-Stephen
                  SDilly
               


Popular Email Services

@gmail.com
@aol.com
@yahoo.com
@comcast.net
@hotmail.com
@msn.com
@rocketmail.com
@att.net
@sbcglobal.net
@ymail.com
@facebook.com
@mail.com
@bellsouth.net
@live.com
@earthlink.net
@cox.net
@prodigy.net
@me.com
@peoplepc.com
@juno.com
@rediffmail.com
@mindspring.com
@comcast.com
@charter.net
@outlook.com




All trademarks, product names, company names or logos on this page are the property of their respective owners.
Related People Searches
S Dilly







         Intelius is a leading provider of public data about people and their connections to others. Intelius does not provide consumer reports and is not a consumer reporting agency as defined by the Fair Credit Reporting Act (FCRA). This site should not be used to determine an individual’s eligibility for credit, insurance, employment, housing or any other purpose covered by the FCRA. For employment or tenant screening services, please visit our partner Talentwise.
      

About Us
Site Map
About Our Reports
Blog
Help
Contact Us

© 2003 – 2017 PeopleConnect, Inc. d/b/a Intelius. All Rights Reserved.
         Privacy Policy - UPDATED
Terms of Service - UPDATED






What is the FCRA?
The Fair Credit Reporting Act ("FCRA") is a federal law that promotes the accuracy, fairness and privacy of information in the files of consumer reporting agencies.
Intelius does not provide consumer reports and is not a consumer reporting agency as defined by the FCRA. Intelius reports cannot be used for background checks related to consumer credit, insurance, employment, housing or any other purpose
                  prohibited under the FCRA.
You may not use any information obtained from Intelius for any purpose covered by the FCRA.
Find out more about the FCRA here.


















Stephen George Dilly Sells 49,400 Shares of Aimmune Therapeutics, Inc. (AIMT) Stock | Daily Political











































































Home
About/Contact
Columnists
Privacy Policy
























Headlines
Politics
Nation
World
Issues
Economy
Finance




















Aimmune Therapeutics Inc. - Get News & Ratings Daily

		Enter your email address below to get the latest news and analysts' ratings for Aimmune Therapeutics Inc. with our FREE daily email newsletter:



 






Follow DailyPolitical

 
 










Latest News



Quest Diagnostics Incorporated (NYSE:DGX) Stake Increased by Contravisory Investment Management Inc.					

Capital Management Associates NY Holds Stake in Macquarie Infrastructure Company (MIC)					

Capital Management Associates NY Has $308,000 Position in OUTFRONT Media Inc. (NYSE:OUT)					

Capital Management Associates NY Reduces Stake in T. Rowe Price Group, Inc. (TROW)					

Capital Management Associates NY Continues to Hold Position in Carpenter Technology Corporation (CRS)					

Western New England Bancorp (NASDAQ:WNEB) Receives “Buy” Rating from Piper Jaffray Companies					

Starbucks Corporation (SBUX) Receives Hold Rating from Wedbush					

The Priceline Group Inc. (NASDAQ:PCLN) Rating Reiterated by Piper Jaffray Companies					

Loop Capital Reiterates Buy Rating for Intel Corporation (INTC)					

Electronic Arts Inc. (NASDAQ:EA) Earns “Buy” Rating from Wedbush					

Lumentum Holdings Inc. (NASDAQ:LITE) Position Held by Capital Management Associates NY					

Capital Management Associates NY Increases Stake in Superior Energy Services, Inc. (NYSE:SPN)					

Albert D Mason Inc. Has $119,000 Stake in Pengrowth Energy Corporation (PGH)					

Albert D Mason Inc. Has $266,000 Stake in Martin Midstream Partners L.P. (NASDAQ:MMLP)					

Apache Corporation (APA) Position Lowered by Albert D Mason Inc.					

Albert D Mason Inc. Has $616,000 Position in Anadarko Petroleum Corporation (NYSE:APC)					

22,526 Shares in DCP Midstream Partners, LP (DCP) Acquired by Albert D Mason Inc.					

Sinovac Biotech (SVA) versus Alimera Sciences (ALIM) Head-To-Head Analysis					

Carter’s (NYSE:CRI) vs. Foot Locker (FL) Critical Comparison					

Dave & Buster’s Entertainment (PLAY) and Cosi (NASDAQ:COSI) Critical Survey					





 





						Stephen George Dilly Sells 49,400 Shares of Aimmune Therapeutics, Inc. (AIMT) Stock					

						 June 29th, 2017  - 0 comments - Filed Under -
 by Jeff Wilder 


							Filed Under: Finance - Insider Trades 







Tweet










Aimmune Therapeutics, Inc. (NASDAQ:AIMT) insider Stephen George Dilly sold 49,400 shares of the stock in a transaction dated Friday, June 23rd. The stock was sold at an average price of $20.21, for a total transaction of $998,374.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 
Stephen George Dilly also recently made the following trade(s): 

On Wednesday, May 10th, Stephen George Dilly sold 600 shares of Aimmune Therapeutics stock. The stock was sold at an average price of $20.15, for a total transaction of $12,090.00. 

Shares of Aimmune Therapeutics, Inc. (NASDAQ:AIMT) opened at 21.09 on Thursday. The company has a 50-day moving average of $18.33 and a 200 day moving average of $20.03. The firm’s market capitalization is $1.06 billion. Aimmune Therapeutics, Inc. has a 52 week low of $9.77 and a 52 week high of $27.31. 




Aimmune Therapeutics (NASDAQ:AIMT) last released its quarterly earnings results on Monday, May 8th. The biotechnology company reported ($0.52) earnings per share for the quarter, topping the consensus estimate of ($0.57) by $0.05.  Equities research analysts anticipate that  Aimmune Therapeutics, Inc. will post ($2.66) earnings per share for the current year. 
WARNING: “Stephen George Dilly Sells 49,400 Shares of Aimmune Therapeutics, Inc. (AIMT) Stock” was first  posted by Daily Political and is owned by of Daily Political. If you are viewing this report on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this report can be read at https://www.dailypolitical.com/2017/06/29/stephen-george-dilly-sells-49400-shares-of-aimmune-therapeutics-inc-aimt-stock.html. 
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Swiss National Bank boosted its position in  Aimmune Therapeutics by 17.5% in the first quarter. Swiss National Bank now owns 36,974 shares of the biotechnology company’s stock valued at $803,000 after buying an additional 5,500 shares during the period.  Zurcher Kantonalbank Zurich Cantonalbank boosted its position in  Aimmune Therapeutics by 454.1% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,979 shares of the biotechnology company’s stock valued at $130,000 after buying an additional 4,900 shares during the period.  C WorldWide Group Holding A S purchased a new position in  Aimmune Therapeutics during the first quarter valued at $4,087,000.  Nationwide Fund Advisors boosted its position in  Aimmune Therapeutics by 23.7% in the first quarter. Nationwide Fund Advisors now owns 20,095 shares of the biotechnology company’s stock valued at $437,000 after buying an additional 3,851 shares during the period.  Finally, Columbus Circle Investors purchased a new position in  Aimmune Therapeutics during the first quarter valued at $897,000. Institutional investors and hedge funds own  69.64% of the company’s stock. 
A number of equities analysts have recently commented on the stock. Zacks Investment Research upgraded shares of Aimmune Therapeutics from a “sell” rating to a “buy” rating and set a $21.00 price objective for the company in a research note on Tuesday, May 16th. ValuEngine upgraded shares of Aimmune Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, June 13th. Finally, Piper Jaffray Companies  restated an “overweight” rating and set a $38.00 price objective on shares of Aimmune Therapeutics in a research note on Wednesday, March 22nd. One investment analyst  has rated the stock with a hold rating and five have assigned  a buy rating to the company. Aimmune Therapeutics  has an average rating of “Buy” and a consensus price target of $33.00.
Aimmune Therapeutics Company Profile
Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.






Receive News & Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.



 
















 Comment on this Post

Click here to cancel reply.



Name (required)

Mail (will not be published) (required)

Website






Wordpress Hashcash needs javascript to work, but your browser has javascript disabled. Your comment will be placed in moderation!




Latest News




Jeff Sessions Spoke of Resigning After Tensions Increase with Trump





President Trump’s Tweets Complicate Already Complicated Week





World Leaders Very Critical of Paris Agreement Decision by Trump





Aide to President Trump Resigns With More Expected





Scud-Class Missile Launched by North Korea














			© DailyPolitical, LLC 2009-2017. All rights reserved. 


Privacy Policy |
			About | Columnists 
			| Contact 



























































Insider Trading - Dilly Stephen George - Form 4 SEC Filings












Home |
Archives |
Products |
About |
Contact |
FAQ |



New User?
Sign Up | 
Sign In









Form 4 Filings


Insider Buys


Significant Buys


Penny StocksInsider Buying


Insider Sales




Insider Buy Sell Ratios


Stock Options


Insider TradingStock Screener


Insider TradingGraph View


Insider Watch





Sec Filings Insider Trading - Dilly Stephen George





Select Time period: 
1 Month
2 Months
3 Months
6 Months
1 Year
2 Years
3 Years
4 Years
All Data
 

     



google

   



yahoo!



Send this page to:  

Blog
  



Digg

  



Reddit

  



Facebook

  



Stumble

  



del.icio.us








Enter Stock Ticker Symbol or Cik:




Cik Lookup...






Search By Company or Insider Name:







"Insiders might sell their shares for any number of reasons, but they buy them for only one:
they think the price will rise"
- Peter Lynch ==>>

What is insider trading>>



Email a friend >>...







Historical filings delayed by 6 months. New user?
Sign Up for real time data.
Existing user?
Sign In

Common stock purchase or sale:



TransactionDate
ReportedDate
Company
Symbol
InsiderRelationship
SharesTraded
AveragePrice
TotalAmount
SharesOwned
Filing




2016-11-10Sale
2016-11-154:05 pm
Aimmune Therapeutics Inc.
AIMT
Dilly Stephen GeorgeSee RemarksDirector
50,000
$25.01
$1,250,590
779,755(DirectIndirect)
View




Stock options: Exercise, Award, Grant, Conversion



TransactionDate
ReportedDate
ExercisableExpiration
Company
Symnbol
InsiderRelationship
SharesTraded
ConversionPrice
SharesOwned
Filing




2016-11-10Gift
2016-11-154:05 pm
N/AN/A
Aimmune Therapeutics Inc.
AIMT
Dilly Stephen GeorgeSee RemarksDirector
14,447
$0
779,755(Direct)
View


2016-11-10Gift
2016-11-154:05 pm
N/AN/A
Aimmune Therapeutics Inc.
AIMT
Dilly Stephen GeorgeSee RemarksDirector
14,447
$0
779,755(Indirect)
View


2016-11-10Gift
2016-11-154:05 pm
N/AN/A
Aimmune Therapeutics Inc.
AIMT
Dilly Stephen GeorgeSee RemarksDirector
14,447
$0
779,755(Indirect)
View


2016-11-10Gift
2016-11-154:05 pm
N/AN/A
Aimmune Therapeutics Inc.
AIMT
Dilly Stephen GeorgeSee RemarksDirector
14,447
$0
779,755(Indirect)
View


2016-11-10Gift
2016-11-154:05 pm
N/AN/A
Aimmune Therapeutics Inc.
AIMT
Dilly Stephen GeorgeSee RemarksDirector
14,447
$0
779,755(Direct)
View


2016-11-10Gift
2016-11-154:05 pm
N/AN/A
Aimmune Therapeutics Inc.
AIMT
Dilly Stephen GeorgeSee RemarksDirector
14,447
$0
779,755(Indirect)
View


2016-11-10Gift
2016-11-154:05 pm
N/AN/A
Aimmune Therapeutics Inc.
AIMT
Dilly Stephen GeorgeSee RemarksDirector
14,447
$0
779,755(Indirect)
View


2016-11-10Gift
2016-11-154:05 pm
N/AN/A
Aimmune Therapeutics Inc.
AIMT
Dilly Stephen GeorgeSee RemarksDirector
14,447
$0
779,755(Indirect)
View


2016-06-14Option Award
2016-06-158:29 pm
N/A2026-06-13
Sangamo Biosciences Inc
SGMO
Dilly Stephen GeorgeDirector
10,000
$5.99
10,000(Direct)
View


2016-02-26Option Award
2016-02-267:41 pm
N/A2026-02-26
Aimmune Therapeutics Inc.
AIMT
Dilly Stephen GeorgeSee RemarksDirector
240,000
$16.93
765,308(Direct)
View


2015-06-22Option Award
2015-06-245:06 pm
N/A2025-06-21
Sangamo Biosciences Inc
SGMO
Dilly Stephen GeorgeDirector
10,000
$11.44
10,000(Direct)
View









    © 2005-2017 SecForm4.Com All rights reserved.
    Archives:
    2017 2016 2015 2014 2013 2012 ... 
    Fri, 28 Jul 2017 06:47:43 -0500
  

    SEC is the U.S. Securities and Exchange Commission. EDGAR is a trademark of the SEC.
    SecForm4.Com is not affiliated with or approved by the U.S. Securities and Exchange Commission (SEC).
Terms of Use |
    Privacy Statement |
  










STEPHEN GEORGE  DILLY - CEO, founder, businessman - profile

















directorpedia.net - List of CEOs, founders, board members and company directors











STEPHEN GEORGE  DILLY
Check out list of companies and businesses related to STEPHEN GEORGE  DILLY. Find out STEPHEN GEORGE  DILLY address and contact details. View other people related to STEPHEN GEORGE  DILLY - coworkers, colleagues, companions, etc.
Address:   

C/O AVIGEN, INC. 1301 HARBOR BAY PKWY ALAMEDA 94502 CA




Companies related to STEPHEN GEORGE  DILLY
CIKCompany NamePositionCompany Address0000932903AVIGEN INC \DEDirector 1301 HARBOR BAY PARKWAY  ALAMEDA 945020001001233SANGAMO THERAPEUTICS, INCDirector 501 CANAL BLVD POINT RICHMOND TECH CNTR. RICHMOND 948040001631650Aimmune Therapeutics, Inc.President and CEO 8000 MARINA BOULEVARD SUITE 300 BRISBANE 94005-1884




STEPHEN GEORGE  DILLY on the Web
Persons related to STEPHEN GEORGE  DILLY - AVIGEN INC \DENamePositionCityBIOTECHNOLOGY VALUE FUND II LPCHICAGOBIOTECHNOLOGY VALUE FUND II LPCHICAGOBIOTECHNOLOGY VALUE FUND L PCHICAGOBIOTECHNOLOGY VALUE FUND L PCHICAGOBURLINGAME ASSET MANAGEMENT, LLC10% Owner SAN FRANCISCOBURLINGAME ASSET MANAGEMENT, LLC10% Owner SAN FRANCISCOBVF Acquisition LLCCHICAGOBVF INC/ILCHICAGOBVF INC/ILSAN FRANCISCOBVF INC/ILCHICAGOBVF INVESTMENTS LLCCHICAGOBVF INVESTMENTS LLCCHICAGOBVF PARTNERS L P/IL10% Owner SAN FRANCISCOBVF PARTNERS L P/IL10% Owner CHICAGOBVF PARTNERS L P/ILCHICAGOKENNETH  CHAHINEChief Executive Officer ALAMEDAKENNETH  CHAHINEChief Executive Officer ALAMEDAKENNETH  CHAHINEChief Executive Officer ALAMEDAKENNETH  CHAHINEChief Executive Officer ALAMEDAKENNETH  CHAHINEDirector ALAMEDAMICHAEL DENIS  COFFEEChief Business Officer ALAMEDAMICHAEL DENIS  COFFEEChief Business Officer ALAMEDAROBERT M  COPPEDGESEATTLESTEPHEN GEORGE  DILLYDirector ALAMEDAHoward  GoldenGREENWICHHoward  GoldenGREENWICHZOLA P  HOROVITZDirector ALAMEDAZOLA P  HOROVITZDirector PLYMOUTH MEETINGZOLA P  HOROVITZDirector ALAMEDAZOLA P  HOROVITZDirector ALAMEDAZOLA P  HOROVITZDirector ALAMEDAYUICHI  IWAKIDirector YUICHI  IWAKIDirector ALAMEDAYUICHI  IWAKIDirector ALAMEDAYUICHI  IWAKIDirector ALAMEDAYUICHI  IWAKIDirector ALAMEDAYUICHI  IWAKIDirector ALAMEDAKirk William  JohnsonVP Research and Development ALAMEDAKirk William  JohnsonVP, Preclinical Development ALAMEDAMARK N  LAMPERTSAN FRANCISCOMARK N  LAMPERTCHICAGODAWN  MCGUIREChief Medical Officer ALAMEDADAWN  MCGUIREChief Medical Officer ALAMEDAOLEG  NODELMANSAN FRANCISCOJAN K  OHRSTROMDirector ALAMEDAJAN K  OHRSTROMDirector ALAMEDATHOMAS J  PAULSONTHOMAS J  PAULSONChief Finance Officer & Secty ALAMEDATHOMAS J  PAULSONChief Finance Officer & Secty ALAMEDATHOMAS J  PAULSONALAMEDAMATTHEW D  PERRYSAN FRANCISCOGLENN  PIERCEVP, Research & Clinical Dvlpt ALAMEDAJOHN K A  PRENDERGASTDirector ALAMEDAJOHN K A  PRENDERGASTDirector ALAMEDAANDREW AUGUST  SAUTERCEO, President and CFO ALAMEDASouthpaw Asset Management LP10% Owner GREENWICHSouthpaw Credit Opportunity Master Fund, L.P.10% Owner GREENWICHSouthpaw Holdings LLCGREENWICHMary Christina  ThomsonVP, Corp Counsel & Secretary ALAMEDAMary Christina  ThomsonVP, Corporate Counsel ALAMEDADANIEL  VAPNEKDirector ALAMEDADANIEL  VAPNEKDirector ALAMEDADANIEL  VAPNEKDirector ALAMEDARichard John  WallaceDirector ALAMEDARichard John  WallaceDirector ALAMEDAPHILIP J  WHITCOMEChairman of the Board of Direc ALAMEDAPHILIP J  WHITCOMEChairman of the Board of Direc ALAMEDAPHILIP J  WHITCOMEChairman of the Board of Direc ALAMEDAKevin  WymanGREENWICHKevin  WymanGREENWICHPersons related to STEPHEN GEORGE  DILLY - SANGAMO THERAPEUTICS, INCNamePositionCityDALE G  ANDOVP, Therapeutic Dev. & CMO SOUTH SAN FRANCISCODALE G  ANDOVP, Therapeutic Dev. & CMO RICHMONDDALE G  ANDORICHMONDDALE G  ANDOVP, Therapeutic Dev. & CMO RICHMONDDALE G  ANDOVP, Therapeutic Dev. & CMO RICHMONDDALE G  ANDOVP, Therapeutic Dev. & CMO RICHMONDDALE G  ANDOVP, Therapeutic Dev. & CMO RICHMONDDALE G  ANDOVP, Therapeutic Dev. & CMO RICHMONDDALE G  ANDOVP, Therapeutic Dev. & CMO RICHMONDPETER  BLUFORDVP, Corporate Development RICHMONDRobert  CareyDirector DEERFIELDCASEY C  CASEVice President, Research RICHMONDCASEY C  CASEVP, Research & Operations RICHMONDPaul B  ClevelandDirector PALO ALTOPaul B  ClevelandDirector RICHMONDPaul B  ClevelandDirector RICHMONDEdward R.  ConnerSenior VP & CMO RICHMONDSTEPHEN GEORGE  DILLYDirector ALAMEDASTEPHEN GEORGE  DILLYDirector RICHMONDSTEPHEN GEORGE  DILLYDirector RICHMONDWILLIAM G  GERBERDirector BOTHELLWILLIAM G  GERBERDirector RICHMONDWILLIAM G  GERBERDirector RICHMONDWILLIAM G  GERBERDirector RICHMONDWILLIAM G  GERBERDirector RICHMONDWILLIAM G  GERBERDirector RICHMONDPhilip D  GregoryVice President, Research & CSO RICHMONDPhilip D  GregorySVP of Research & CSO RICHMONDPhilip D  GregorySVP, Research & CSO RICHMONDPhilip D  GregorySVP of Research & CSO RICHMONDPhilip D  GregoryVice President, Research RICHMONDPhilip D  GregoryVice President, Research RICHMONDPhilip D  GregoryVice President, Research RICHMONDPhilip D  GregoryCSO & Vice President, Research RICHMONDPhilip D  GregorySVP of Research & CSO RICHMONDPhilip D  GregoryCSO & Vice President, Research RICHMONDCurt A.  Herberts IIISr.VP & Chief Business Officer RICHMONDDavid G  IchikawaRICHMONDDavid G  IchikawaSenior VP, Bus. Dev. RICHMONDDavid G  IchikawaSenior VP, Bus. Dev. RICHMONDDavid G  IchikawaSenior VP, Bus. Dev. RICHMONDDavid G  IchikawaSenior VP, Bus. Dev. RICHMONDDavid G  IchikawaSenior VP, Bus. Dev. RICHMONDDavid G  IchikawaSenior VP, Bus. Dev. RICHMONDDavid G  IchikawaSenior VP, Bus. Dev. RICHMONDJON E M  JACOBYDirector LITTLE ROCKJON E M  JACOBYDirector RICHMONDROGER  JEFFSDirector Peter  KolchinskyBOSTONLeRoy C  Kopp10% Owner EDINAEDWARD O  LANPHIER IIDirector RICHMONDEDWARD O  LANPHIER IIRICHMONDEDWARD O  LANPHIER IIPres and Chief Ex Officer RICHMONDEDWARD O  LANPHIER IIPresident & Chief Exec Officer RICHMONDEDWARD O  LANPHIER IIPresident & CEO RICHMONDEDWARD O  LANPHIER IIRICHMONDEDWARD O  LANPHIER IIPresident & CEO RICHMONDEDWARD O  LANPHIER IIPresident & CEO RICHMONDEDWARD O  LANPHIER IIPresident & CEO RICHMONDEDWARD O  LANPHIER IIRICHMONDEDWARD O  LANPHIER IIPresident & CEO RICHMONDEDWARD O  LANPHIER IIPresident and CEO RICHMONDEDWARD O  LANPHIER IIPresident & CEO RICHMONDEDWARD O  LANPHIER IIPresident and CEO RICHMONDEDWARD O  LANPHIER IIPresident & CEO RICHMONDEDWARD O  LANPHIER IIPresident and CEO RICHMONDEDWARD O  LANPHIER IIPresident & CEO RICHMONDEDWARD O  LANPHIER IIRICHMONDEDWARD O  LANPHIER IIPres & Chief Ex Officer RICHMONDJOHN WILLIAM  LARSONDirector RICHMONDJOHN WILLIAM  LARSONDirector RICHMONDJOHN WILLIAM  LARSONDirector RICHMONDJOHN WILLIAM  LARSONDirector RICHMONDJOHN WILLIAM  LARSONDirector RICHMONDJOHN WILLIAM  LARSONDirector RICHMONDJOHN WILLIAM  LARSONDirector RICHMONDJOHN WILLIAM  LARSONDirector RICHMONDJOHN WILLIAM  LARSONDirector RICHMONDJOHN WILLIAM  LARSONDirector RICHMONDJOHN WILLIAM  LARSONDirector RICHMONDMargaret  LiuDirector RICHMONDMargaret  LiuDirector RICHMONDSandy  MacraePresident and CEO RICHMONDSteven J  MentoDirector RICHMONDSteven J  MentoDirector RICHMONDSteven J  MentoDirector RICHMONDSteven J  MentoDirector RICHMONDSteven J  MentoDirector RICHMONDGEOFFREY  NICHOLExecutive Vice President, R&D PRINCETONGEOFFREY  NICHOLExecutive Vice President, R&D RICHMONDGEOFFREY  NICHOLExecutive Vice President, R&D RICHMONDGEOFFREY  NICHOLExecutive Vice President, R&D RICHMONDH STEWART  PARKERDirector SEATTLEH STEWART  PARKERDirector RICHMONDRA Capital Healthcare Fund LPBOSTONRA CAPITAL MANAGEMENT, LLC BOSTONRA CAPITAL MANAGEMENT, LLC BOSTONSaira  RamasastryDirector RICHMONDSaira  RamasastryDirector RICHMONDWILLIAM R  RINGODirector WILLIAM R  RINGODirector RICHMONDWILLIAM R  RINGODirector RICHMONDWILLIAM R  RINGORICHMONDWILLIAM J  RUTTERDirector THOMAS G  WIGGANSDirector RICHMONDTHOMAS G  WIGGANSDirector RICHMONDTHOMAS G  WIGGANSDirector RICHMONDHenry Ward  WolffExec VP & CFO FREMONTHenry Ward  WolffExec VP & CFO RICHMONDHenry Ward  WolffExec VP & CFO RICHMONDHenry Ward  WolffExec VP & CFO RICHMONDHenry Ward  WolffDirector RICHMONDHenry Ward  WolffExec VP & CFO RICHMONDHenry Ward  WolffExec VP & CFO RICHMONDHenry Ward  WolffExec VP & CFO RICHMONDHenry Ward  WolffExec VP & CFO RICHMONDMICHAEL C  WOODDirector MICHAEL C  WOODDirector RICHMONDMICHAEL C  WOODDirector RICHMONDMICHAEL C  WOODDirector RICHMONDKathy  YiSenior VP & CFO RICHMONDJoseph S  ZakrzewskiDirector SOMERSETGREG  ZANTESr Dir., Finance and Admin RICHMONDGREG  ZANTESr Dir., Finance & Admin RICHMONDGREG  ZANTESr. Director Finance & Admin RICHMONDGREG  ZANTEVP, Finance & Administration RICHMONDGREG  ZANTEVice President, Fin. & Admin. RICHMONDGREG  ZANTEVice President, Fin. & Admin. RICHMONDGREG  ZANTEVP, Finance & Administration RICHMONDPersons related to STEPHEN GEORGE  DILLY - Aimmune Therapeutics, Inc.NamePositionCityDANIEL C MD  ADELMANChief Medical Officer SOUTH SAN FRANCISCOSusan E.  BarrowcliffeGeneral Manager, Europe BRISBANEGregory  BeharDirector CAMBRIDGEERIC  BJERKHOLTChief Financial Officer PALO ALTOWalser  BryanSan MateoWarren L.  DeSouzaChief Financial Officer BRISBANESTEPHEN GEORGE  DILLYPresident and CEO ALAMEDARobert Myles  ElfontChief Medical Officer BRISBANEPATRICK G  ENRIGHTDirector BURLINGAMEKATHRYN E  FALBERGDirector ROCKVILLEForesite Capital Fund II, L.P.SAN FRANCISCOForesite Capital Fund III, L.P.SAN FRANCISCOForesite Capital Management II, LLC10% Owner SAN FRANCISCOForesite Capital Management III, LLCSAN FRANCISCOMark T  IwickiDirector MARLBOROUGHTananbaum  JamesSan Francisco(Anthony)  Yun  JoonkyooSan MateoJeffrey H  KnappChief Operating Officer FREMONTLongitude Capital Partners II, LLC10% Owner MENLO PARKLongitude Venture Partners II, L.P.MENLO PARKMARK  MCDADEDirector Nestle Health Science US Holdings, Inc.NORWALKSA  NESTLEVEVEY, SWITZERLANDNIMCO US, Inc.NORWALKEnright  PatrickMenlo ParkHoward V.  RaffBRISBANEMary M.  RozenmanSee Remarks BRISBANEStacey Denenberg  SeltzerDirector BRISBANEDouglas T.  SheehySee Remarks REDWOOD CITYSeltzer  StaceyNew YorkDilly, Jr.  StephenSan MateoBakker Juliet  TammenomsMENLO PARKJames B.  TananbaumSAN FRANCISCOColunga  VictorSan Mateo
Potentially same personNameCityCountryGeorge  StephenPalo AltoCAGeorge  StephenPalo AltoCAGeorge  StephenOmahaNEGeorge  StephenOmahaNEGeorge  StephenOmahaNEGeorge  StephenOmahaNEGeorge  StephenLos AngelesCAGeorge  StephenOaklandCAGeorge  StephenOmahaNE












 









Microsoft personalized ad preferences




 













To opt out of personalized ads in this browser, your browser history must allow first-party and third-party cookies and you must have your browsing experience set to NOT delete browsing history on exit. Instructions for enabling cookies and configuring your browsing history may be available in your browsers settings, privacy, or help documentation.

















Sign in
















  Hold on… We’re sorry but this didn’t work.                  You can’t turn off personalized ads right now because your browser is currently blocking third-party cookies. We can help you fix this issue.                Let’s get started:  Depending on what browser you use, open Options or Settings.                  Make sure that third-party cookies are not blocked anymore. To find out how, search your browser’s Help.                                 Revisit http://choice.microsoft.com/opt-out, and then on the “Personalized ads in this browser” tile, click Off.                 ext74081 




  About Our Ads To create a more customized online experience, some of the ads you may receive on Microsoft websites and apps are tailored to your previous activities, searches and site visits. You're in control and here's where you can make the advertising choice that's right for you. ext74075 




  Where Can I Learn More about Advertising on Microsoft Websites and Apps? Microsoft partners with Oath, AppNexus and other third party service providers to help present customized content and display advertisements on MSN, Outlook.com and other websites and apps. Microsoft also delivers search ads to Bing and our search syndication partners. Learn more about Microsoft’s privacy practices here. You can learn more about interest-based ads from Oath and AppNexus in their privacy statements: Oath and AppNexus. What Choices Do I Have About Interest-Based Advertising? On this page, you can opt out of receiving interest based advertising from Microsoft. You can also opt out of receiving interest-based advertising from all self-regulatory members, including Microsoft, Oath, AppNexus and other third party ad networks, at the following sites:  In the US: Digital Advertising Alliance (DAA) In Europe: European Interactive Digital Advertising Alliance (EDAA) In Canada: Ad Choices: Digital Advertising Alliance of Canada (DAAC)  You can control interest-based advertising in Windows apps by turning off the advertising ID in Windows Settings.  More choices  Do you want personalized ads from other companies?  Questions? If you have a privacy question or a question for the Chief Privacy Officer of Microsoft, please contact us by using our web form. We will respond to questions within 30 days. ext74076 




       Personalized ads in this browser     OFF    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting for this web browser.  Learn more           If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.          ext74078 




       Personalized ads wherever I use my Microsoft account     OFF   Sign in to change...    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting that applies when you are signed in on any computer or device with your Microsoft account, including Windows, Windows phone, Xbox and other devices.  Learn more                    If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.         If you choose “generic” ads and use a browser, your choice applies to everyone when using that browser as long as you do not clear your cookies.          ext74079 




       Personalized ads in Windows         In your Windows Settings, you can turn off personalized ads that appear in apps on this device. You’ll still see ads, but they won’t be personalized anymore.     If you have Windows 8.1:            Access the charms by touching or moving your pointer to the right edge of the screen.                 Click or tap Settings, and then click or tap Change PC Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have Windows 10:            Click or tap the Start button.                 Click or tap Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have a Windows mobile device:            Go to Settings.                 Tap on Privacy.                 Tap on Advertising ID, and then turn off Let apps use my advertising ID for experiences across apps.                If you want to turn off personalized ads from Microsoft wherever you use your Microsoft account including apps on Windows, Windows Phone, Xbox and other devices, you can do so by selecting the Microsoft account option above.    ext74080 














Legal
Privacy & Cookies
© 2017 Microsoft











Stephen George Dilly M.B.B.S, Ph.D.: Executive Profile & Biography - Bloomberg









































  





















































































July 28, 2017 7:47 AM ET
Biotechnology

Company Overview of Aimmune Therapeutics, Inc.



SnapshotPeople 




OverviewBoard MembersCommittees



Executive Profile
Stephen George Dilly M.B.B.S, Ph.D.Chief Executive Officer, President and Director, Aimmune Therapeutics, Inc.AgeTotal Calculated CompensationThis person is connected to 4 Board Members in 4 different organizations across 5 different industries.See Board Relationships57$3,335,832As of Fiscal Year 2016
Background

		Dr. Stephen George Dilly, M.B.B.S, Ph.D., has been the Chief Executive Officer of Aimmune Therapeutics, Inc. since April 2014 and also serves as its President. Dr. Dilly serves as Strategic Advisor at Physic Ventures, LLC. He served as the Chief Executive officer of PhotoThera, Inc. from January 2012 to December 2012 and also served as its President. He served as Chief Executive Officer and President at APT Pharmaceutical LLC from April 2006 to December 2011. He has ... extensive drug development experience. From October 2003 to April 2006, he served as the Senior Vice President, Head of Development and Chief Medical Officer at Chiron Biopharmaceuticals in Emeryville, California, where he was responsible for all clinical, regulatory, development and medical-marketing activities worldwide. Prior to joining APT, Dr. Dilly held a number of senior executive clinical, development and commercial support positions at leading pharmaceutical and biotechnology companies including Smithkline Beecham and Genentech, Inc. Prior to joining Chiron, he served as the Senior Vice President of Development Sciences and Chief Medical Officer and Head of Clinical, Head of Development Sciences, Vice President for Clinical R&D and Medical Affairs from 1998 to 2001 for Genentech in South San Francisco from September 1998 to September 2003. He was the Vice President of Development Sciences at Genentech Inc. from 2002 to 2003. Dr. Dilly also held executive positions at Central Research in the United Kingdom and was the Vice President of CardioPulmonary and Clinical Neuroscience at SmithKline Beecham in the United States and the United Kingdom. He has played important roles in the development and approval of numerous drugs including Kytril(R), Requip(R), Kredex(R), Paxil CR(R), Cathflo(R) Activase(R), Raptiva(R), Xolair(R), Avastin(R), Lucentis, Cubicin and Tarceva(R). He serves as non-Executive Chairman of the Allergen Research Corporation Inc. and serves on the National Board of Advisors of the UC Davis Health System. He has been a Director of Aimmune Therapeutics, Inc. since April 2013. He serves as Member of Advisory Board at BDC Health Venture Fund. He serves as a Member of Advisory Board at Physic Ventures, LLC. He has been an Independent Director of Sangamo Therapeutics, Inc. since March 31, 2010. He served as a Director of PhotoThera, Inc. He served as a Director of APT Pharmaceuticals, Inc., from April 2006 to December 2011. He served as a Director of Avigen Inc., from February 6, 2007 to 2009. In 1982, Dr. Dilly received an M.B.B.S., the equivalent of an M.D. in the U.S., from the University of London in the U.K. and a Ph.D. in Cardiac Physiology from University of London in 1988.Read Full Background




Corporate Headquarters
8000 Marina BoulevardBrisbane, California 94005United StatesPhone: 650-614-5220Fax: 650-616-0075
Board Members Memberships
2010-PresentIndependent DirectorSangamo Therapeutics, Inc.2013-PresentChief Executive Officer, President and DirectorAimmune Therapeutics, Inc.
Education
PhD 1988University Of LondonBachelor's Degree 1982University Of London
Other Affiliations
Avigen, Inc.Genentech, Inc.Sangamo Therapeutics, Inc.PhotoThera, Inc.University Of LondonAPT Pharmaceuticals, Inc.Physic Ventures, LLCBDC Health Venture Fund


Annual Compensation
Salary$440,000Total Annual Compensation$440,000
Stocks Options
Exercisable Options$645,942Exercisable Options Value$10,563,269Unexercisable Options$190,000Unexercisable Options Value$668,800Total Value of Options$11,232,069Total Number of Options$835,942
Total Compensation
Total Annual Cash Compensation$660,000Total Short Term Compensation$440,000Total Calculated Compensation$3,335,832




Request Profile Update
















 












The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking 
	here.




Stock Quotes


Market data is delayed at least 15 minutes.







Company Lookup



COMPETITOR COMPENSATIONNamePosition/CompanyCompensationPierre-Henri  Benhamou M.D.Co-Founder, Chairman and Chief Executive OfficerDBV Technologies S.A.$650.3KCompensation as of Fiscal Year 2016.










Sponsored Financial Commentaries

Sponsored Links






Browse Companies
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
 | 
0
1
2
3
4
5
6
7
8
9






Request Profile Update

						Only a company representative may request an update for the company profile. Documentation will be required.
					  
To contact Aimmune Therapeutics, Inc., please visit .  Company data is provided by S&P Global Market Intelligence.  Please use this form to report any data issues.
					  


Information Missing - Please enter your information in the following field(s): 




Company Name

Your Name*

Your E-Mail Address*

Your Phone Number*

Type of Data*


Overview
Executives
Key developments
Similar companies
Transactions


Update Needed*

All data changes require verification from public sources.  Please include the correct value or values and a source where we can verify.


Cancel


Submit






Your requested update has been submitted
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.


Close





























 SECGems: DILLY STEPHEN GEORGE 







































  







			Data feeds now available
			Excel / CSV / Java / Python /etc 
Database
Learn more









  




  


  






























 DILLY STEPHEN GEORGE 
		     










 Info




 Ownership




 Filings














←


 1 


→



 Ownership filings:    (1 of 20 - Total: 20)








Filing date
2017-06-27
Submission
 0000899243-17-017282.nc

Form
4  Ownership: Statement of changes in beneficial ownership. Insider trading ( Directors, Officers, Significant Shareholders )
Issuer
 Aimmune Therapeutics, Inc.  AIMT

Reporting Owner
 DILLY STEPHEN GEORGE
[
				      
				        Director,  
				        Officer, 
				       President and CEO, 
				      
				      
				      ]







Type
Title
Conv/Exer price
Trans. date
Deemed Exe date
Trans Form Type
Trans Code
Eqty swap?
Footnote id
Trans timelines
# Shares
Value
Total Value
Price / share
Acq or Disp
Date exercisable
Expiration date
# Owned post trans
Value Owned post trans
Underlying security title
# Underlying securities
Value underlying securities
Direct or Indirect own
Nature indirect own

Non-Derriv. transCommon Stock, $0.0001 par value2017-06-234S : Open market or private saleFalse4940020.2144D665308D
Non-Derriv. holdingCommon Stock, $0.0001 par value51403IBy GRAT 1
Non-Derriv. holdingCommon Stock, $0.0001 par value14447IBy GRAT 2
Non-Derriv. holdingCommon Stock, $0.0001 par value51403IBy Wife's GRAT 1
Non-Derriv. holdingCommon Stock, $0.0001 par value14447IBy Wife's GRAT 2












Filing date
2017-06-07
Submission
 0001140361-17-024394.nc

Form
4  Ownership: Statement of changes in beneficial ownership. Insider trading ( Directors, Officers, Significant Shareholders )
Issuer
 SANGAMO THERAPEUTICS, INC  SGMO

Reporting Owner
 DILLY STEPHEN GEORGE
[
				      
				        Director,  
				      
				      
				      
				      
				      ]







Type
Title
Conv/Exer price
Trans. date
Deemed Exe date
Trans Form Type
Trans Code
Eqty swap?
Footnote id
Trans timelines
# Shares
Value
Total Value
Price / share
Acq or Disp
Date exercisable
Expiration date
# Owned post trans
Value Owned post trans
Underlying security title
# Underlying securities
Value underlying securities
Direct or Indirect own
Nature indirect own

Derriv. transStock Option (Right to Buy)7.22017-06-054A : Grant / awardFalse100000A2027-06-0410000Common Stock10000D












Filing date
2017-05-12
Submission
 0000899243-17-012977.nc

Form
4  Ownership: Statement of changes in beneficial ownership. Insider trading ( Directors, Officers, Significant Shareholders )
Issuer
 Aimmune Therapeutics, Inc.  AIMT

Reporting Owner
 DILLY STEPHEN GEORGE
[
				      
				        Director,  
				        Officer, 
				       See Remarks, 
				      
				      
				      ]







Type
Title
Conv/Exer price
Trans. date
Deemed Exe date
Trans Form Type
Trans Code
Eqty swap?
Footnote id
Trans timelines
# Shares
Value
Total Value
Price / share
Acq or Disp
Date exercisable
Expiration date
# Owned post trans
Value Owned post trans
Underlying security title
# Underlying securities
Value underlying securities
Direct or Indirect own
Nature indirect own

Non-Derriv. transCommon Stock, $0.0001 par value2017-05-104S : Open market or private saleFalse60020.15D714708D
Non-Derriv. holdingCommon Stock, $0.0001 par value51403IBy GRAT 1
Non-Derriv. holdingCommon Stock, $0.0001 par value14447IBy GRAT 2
Non-Derriv. holdingCommon Stock, $0.0001 par value51403IBy Wife's GRAT 1
Non-Derriv. holdingCommon Stock, $0.0001 par value14447IBy Wife's GRAT 2












Filing date
2017-02-24
Submission
 0000899243-17-005266.nc

Form
4  Ownership: Statement of changes in beneficial ownership. Insider trading ( Directors, Officers, Significant Shareholders )
Issuer
 Aimmune Therapeutics, Inc.  AIMT

Reporting Owner
 DILLY STEPHEN GEORGE
[
				      
				        Director,  
				        Officer, 
				       See Remarks, 
				      
				      
				      ]







Type
Title
Conv/Exer price
Trans. date
Deemed Exe date
Trans Form Type
Trans Code
Eqty swap?
Footnote id
Trans timelines
# Shares
Value
Total Value
Price / share
Acq or Disp
Date exercisable
Expiration date
# Owned post trans
Value Owned post trans
Underlying security title
# Underlying securities
Value underlying securities
Direct or Indirect own
Nature indirect own

Non-Derriv. holdingCommon Stock, $0.0001 par value715308D
Non-Derriv. holdingCommon Stock, $0.0001 par value51403IBy GRAT 1
Non-Derriv. holdingCommon Stock, $0.0001 par value14447IBy GRAT 2
Non-Derriv. holdingCommon Stock, $0.0001 par value51403IBy Wife's GRAT 1
Non-Derriv. holdingCommon Stock, $0.0001 par value14447IBy Wife's GRAT 2
Derriv. transStock Option (right to buy)19.632017-02-244A : Grant / awardFalse2400000.00A2027-02-24240000Common Stock240000D












Filing date
2016-11-15
Submission
 0000899243-16-033506.nc

Form
4  Ownership: Statement of changes in beneficial ownership. Insider trading ( Directors, Officers, Significant Shareholders )
Issuer
 Aimmune Therapeutics, Inc.  AIMT

Reporting Owner
 DILLY STEPHEN GEORGE
[
				      
				        Director,  
				        Officer, 
				       See Remarks, 
				      
				      
				      ]







Type
Title
Conv/Exer price
Trans. date
Deemed Exe date
Trans Form Type
Trans Code
Eqty swap?
Footnote id
Trans timelines
# Shares
Value
Total Value
Price / share
Acq or Disp
Date exercisable
Expiration date
# Owned post trans
Value Owned post trans
Underlying security title
# Underlying securities
Value underlying securities
Direct or Indirect own
Nature indirect own

Non-Derriv. transCommon Stock, $0.0001 par value2016-07-255G : GiftFalseE144470.00A779755D
Non-Derriv. transCommon Stock, $0.0001 par value2016-07-255G : GiftFalseE144470.00D51403IBy GRAT 1
Non-Derriv. transCommon Stock, $0.0001 par value2016-07-255G : GiftFalseE144470.00A14447IBy Wife
Non-Derriv. transCommon Stock, $0.0001 par value2016-07-255G : GiftFalseE144470.00D51403IBy Wife's GRAT 1
Non-Derriv. transCommon Stock, $0.0001 par value2016-08-245G : GiftFalseE144470.00D765308D
Non-Derriv. transCommon Stock, $0.0001 par value2016-08-245G : GiftFalseE144470.00A14447IBy GRAT 2
Non-Derriv. transCommon Stock, $0.0001 par value2016-08-245G : GiftFalseE144470.00D0IBy Wife
Non-Derriv. transCommon Stock, $0.0001 par value2016-08-245G : GiftFalseE144470.00A14447IBy Wife's GRAT 2
Non-Derriv. transCommon Stock, $0.0001 par value2016-11-104S : Open market or private saleFalse130425.00D764004D
Non-Derriv. transCommon Stock, $0.0001 par value2016-11-114S : Open market or private saleFalse2369625.0249D740308D
Non-Derriv. transCommon Stock, $0.0001 par value2016-11-114S : Open market or private saleFalse2500025.00D715308D












Filing date
2016-06-15
Submission
 0001140361-16-069931.nc

Form
4  Ownership: Statement of changes in beneficial ownership. Insider trading ( Directors, Officers, Significant Shareholders )
Issuer
 SANGAMO BIOSCIENCES INC  SGMO

Reporting Owner
 DILLY STEPHEN GEORGE
[
				      
				        Director,  
				      
				      
				      
				      
				      ]







Type
Title
Conv/Exer price
Trans. date
Deemed Exe date
Trans Form Type
Trans Code
Eqty swap?
Footnote id
Trans timelines
# Shares
Value
Total Value
Price / share
Acq or Disp
Date exercisable
Expiration date
# Owned post trans
Value Owned post trans
Underlying security title
# Underlying securities
Value underlying securities
Direct or Indirect own
Nature indirect own

Derriv. transStock Option (Right to Buy)5.992016-06-144A : Grant / awardFalse100000A2026-06-1310000Common Stock10000D












Filing date
2016-02-26
Submission
 0000899243-16-014620.nc

Form
4  Ownership: Statement of changes in beneficial ownership. Insider trading ( Directors, Officers, Significant Shareholders )
Issuer
 Aimmune Therapeutics, Inc.  AIMT

Reporting Owner
 DILLY STEPHEN GEORGE
[
				      
				        Director,  
				        Officer, 
				       See Remarks, 
				      
				      
				      ]







Type
Title
Conv/Exer price
Trans. date
Deemed Exe date
Trans Form Type
Trans Code
Eqty swap?
Footnote id
Trans timelines
# Shares
Value
Total Value
Price / share
Acq or Disp
Date exercisable
Expiration date
# Owned post trans
Value Owned post trans
Underlying security title
# Underlying securities
Value underlying securities
Direct or Indirect own
Nature indirect own

Non-Derriv. holdingCommon Stock, $0.0001 par value765308D
Non-Derriv. holdingCommon Stock, $0.0001 par value65850IBy GRAT
Non-Derriv. holdingCommon Stock, $0.0001 par value65850IBy Wife's GRAT
Derriv. transStock Option (right to buy)16.932016-02-264A : Grant / awardFalse2400000.00A2026-02-26240000Common Stock240000D












Filing date
2015-08-05
Submission
 0000899243-15-002472.nc

Form
3  Ownership: Initial statement of beneficial ownership of securities. Insider trading ( Directors, Officers, Significant Shareholders )
Issuer
 Aimmune Therapeutics, Inc.  AIMT

Reporting Owner
 DILLY STEPHEN GEORGE
[
				      
				        Director,  
				        Officer, 
				       President and CEO, 
				      
				      
				      ]







Type
Title
Conv/Exer price
Trans. date
Deemed Exe date
Trans Form Type
Trans Code
Eqty swap?
Footnote id
Trans timelines
# Shares
Value
Total Value
Price / share
Acq or Disp
Date exercisable
Expiration date
# Owned post trans
Value Owned post trans
Underlying security title
# Underlying securities
Value underlying securities
Direct or Indirect own
Nature indirect own

Non-Derriv. holdingCommon Stock, $0.0001 par value765308D
Non-Derriv. holdingCommon Stock, $0.0001 par value65850IBy GRAT
Non-Derriv. holdingCommon Stock, $0.0001 par value65850IByWife's GRAT
Derriv. holdingStock Option (Right to Buy)3.02212025-05-18Common Stock595942D












Filing date
2015-06-24
Submission
 0001140361-15-025332.nc

Form
4  Ownership: Statement of changes in beneficial ownership. Insider trading ( Directors, Officers, Significant Shareholders )
Issuer
 SANGAMO BIOSCIENCES INC  SGMO

Reporting Owner
 DILLY STEPHEN GEORGE
[
				      
				        Director,  
				      
				      
				      
				      
				      ]







Type
Title
Conv/Exer price
Trans. date
Deemed Exe date
Trans Form Type
Trans Code
Eqty swap?
Footnote id
Trans timelines
# Shares
Value
Total Value
Price / share
Acq or Disp
Date exercisable
Expiration date
# Owned post trans
Value Owned post trans
Underlying security title
# Underlying securities
Value underlying securities
Direct or Indirect own
Nature indirect own

Derriv. transStock Option (Right to Buy)11.442015-06-224A : Grant / awardFalse100000A2025-06-2110000Common Stock10000D












Filing date
2014-04-23
Submission
 0001209191-14-028960.nc

Form
4  Ownership: Statement of changes in beneficial ownership. Insider trading ( Directors, Officers, Significant Shareholders )
Issuer
 SANGAMO BIOSCIENCES INC  SGMO

Reporting Owner
 DILLY STEPHEN GEORGE
[
				      
				        Director,  
				      
				      
				      
				      
				      ]







Type
Title
Conv/Exer price
Trans. date
Deemed Exe date
Trans Form Type
Trans Code
Eqty swap?
Footnote id
Trans timelines
# Shares
Value
Total Value
Price / share
Acq or Disp
Date exercisable
Expiration date
# Owned post trans
Value Owned post trans
Underlying security title
# Underlying securities
Value underlying securities
Direct or Indirect own
Nature indirect own

Derriv. transStock Option (Right to Buy)14.202014-04-214A : Grant / awardFalse100000.00A2024-04-2010000Common Stock10000D












Filing date
2013-06-14
Submission
 0001181431-13-034996.nc

Form
4  Ownership: Statement of changes in beneficial ownership. Insider trading ( Directors, Officers, Significant Shareholders )
Issuer
 SANGAMO BIOSCIENCES INC  SGMO

Reporting Owner
 DILLY STEPHEN GEORGE
[
				      
				        Director,  
				      
				      
				      
				      
				      ]







Type
Title
Conv/Exer price
Trans. date
Deemed Exe date
Trans Form Type
Trans Code
Eqty swap?
Footnote id
Trans timelines
# Shares
Value
Total Value
Price / share
Acq or Disp
Date exercisable
Expiration date
# Owned post trans
Value Owned post trans
Underlying security title
# Underlying securities
Value underlying securities
Direct or Indirect own
Nature indirect own

Derriv. transStock Option (Right to Buy)7.772013-06-124A : Grant / awardFalse100000A2023-06-1110000Common Stock10000D












Filing date
2012-06-25
Submission
 0001181431-12-037881.nc

Form
4  Ownership: Statement of changes in beneficial ownership. Insider trading ( Directors, Officers, Significant Shareholders )
Issuer
 SANGAMO BIOSCIENCES INC  SGMO

Reporting Owner
 DILLY STEPHEN GEORGE
[
				      
				        Director,  
				      
				      
				      
				      
				      ]







Type
Title
Conv/Exer price
Trans. date
Deemed Exe date
Trans Form Type
Trans Code
Eqty swap?
Footnote id
Trans timelines
# Shares
Value
Total Value
Price / share
Acq or Disp
Date exercisable
Expiration date
# Owned post trans
Value Owned post trans
Underlying security title
# Underlying securities
Value underlying securities
Direct or Indirect own
Nature indirect own

Derriv. transStock Option (Right to Buy)5.032012-06-214A : Grant / awardFalse100000A2022-06-2010000Common Stock10000D












Filing date
2011-06-03
Submission
 0001181431-11-034868.nc

Form
4  Ownership: Statement of changes in beneficial ownership. Insider trading ( Directors, Officers, Significant Shareholders )
Issuer
 SANGAMO BIOSCIENCES INC  SGMO

Reporting Owner
 DILLY STEPHEN GEORGE
[
				      
				        Director,  
				      
				      
				      
				      
				      ]







Type
Title
Conv/Exer price
Trans. date
Deemed Exe date
Trans Form Type
Trans Code
Eqty swap?
Footnote id
Trans timelines
# Shares
Value
Total Value
Price / share
Acq or Disp
Date exercisable
Expiration date
# Owned post trans
Value Owned post trans
Underlying security title
# Underlying securities
Value underlying securities
Direct or Indirect own
Nature indirect own

Derriv. transStock Option (Right to Buy)6.412011-06-014A : Grant / awardFalse100000A2021-05-3110000Common Stock10000D












Filing date
2010-04-02
Submission
 0001181431-10-019903.nc

Form
3  Ownership: Initial statement of beneficial ownership of securities. Insider trading ( Directors, Officers, Significant Shareholders )
Issuer
 SANGAMO BIOSCIENCES INC  SGMO

Reporting Owner
 DILLY STEPHEN GEORGE
[
				      
				        Director,  
				      
				      
				      
				      
				      ]







Type
Title
Conv/Exer price
Trans. date
Deemed Exe date
Trans Form Type
Trans Code
Eqty swap?
Footnote id
Trans timelines
# Shares
Value
Total Value
Price / share
Acq or Disp
Date exercisable
Expiration date
# Owned post trans
Value Owned post trans
Underlying security title
# Underlying securities
Value underlying securities
Direct or Indirect own
Nature indirect own













Filing date
2010-04-02
Submission
 0001181431-10-019906.nc

Form
4  Ownership: Statement of changes in beneficial ownership. Insider trading ( Directors, Officers, Significant Shareholders )
Issuer
 SANGAMO BIOSCIENCES INC  SGMO

Reporting Owner
 DILLY STEPHEN GEORGE
[
				      
				        Director,  
				      
				      
				      
				      
				      ]







Type
Title
Conv/Exer price
Trans. date
Deemed Exe date
Trans Form Type
Trans Code
Eqty swap?
Footnote id
Trans timelines
# Shares
Value
Total Value
Price / share
Acq or Disp
Date exercisable
Expiration date
# Owned post trans
Value Owned post trans
Underlying security title
# Underlying securities
Value underlying securities
Direct or Indirect own
Nature indirect own

Derriv. transStock Option (Right to Buy)5.422010-03-314A : Grant / awardFalse500000.00A2020-03-3050000Common Stock50000D












Filing date
2009-12-21
Submission
 0000932903-09-000003.nc

Form
4  Ownership: Statement of changes in beneficial ownership. Insider trading ( Directors, Officers, Significant Shareholders )
Issuer
 AVIGEN INC \DE  AVGN

Reporting Owner
 DILLY STEPHEN GEORGE
[
				      
				        Director,  
				      
				      
				      
				      
				      ]







Type
Title
Conv/Exer price
Trans. date
Deemed Exe date
Trans Form Type
Trans Code
Eqty swap?
Footnote id
Trans timelines
# Shares
Value
Total Value
Price / share
Acq or Disp
Date exercisable
Expiration date
# Owned post trans
Value Owned post trans
Underlying security title
# Underlying securities
Value underlying securities
Direct or Indirect own
Nature indirect own

Derriv. transStock Option (Right to Buy)6.042009-12-184D : Disp to issuerFalse300000D2017-02-050Common Stock $0.001 par value30000D
Derriv. transStock Option (Right to Buy)6.732009-12-184D : Disp to issuerFalse66670D2017-05-300Common Stock $0.001 par value6667D
Derriv. transStock Option (Right to Buy)2.962009-12-184D : Disp to issuerFalse200000D2018-05-190Common Stock $0.001 par value20000D












Filing date
2008-05-19
Submission
 0000932903-08-000005.nc

Form
4  Ownership: Statement of changes in beneficial ownership. Insider trading ( Directors, Officers, Significant Shareholders )
Issuer
 AVIGEN INC \DE  AVGN

Reporting Owner
 DILLY STEPHEN GEORGE
[
				      
				        Director,  
				      
				      
				      
				      
				      ]







Type
Title
Conv/Exer price
Trans. date
Deemed Exe date
Trans Form Type
Trans Code
Eqty swap?
Footnote id
Trans timelines
# Shares
Value
Total Value
Price / share
Acq or Disp
Date exercisable
Expiration date
# Owned post trans
Value Owned post trans
Underlying security title
# Underlying securities
Value underlying securities
Direct or Indirect own
Nature indirect own

Derriv. transNon-Qualified Stock Options (Right to Buy)2.962008-05-194A : Grant / awardFalse200000A2018-05-1920000Common stock $0.001 par value20000D












Filing date
2007-07-16
Submission
 0000932903-07-000020.nc

Form
4  Ownership: Statement of changes in beneficial ownership. Insider trading ( Directors, Officers, Significant Shareholders )
Issuer
 AVIGEN INC \DE  AVGN

Reporting Owner
 DILLY STEPHEN GEORGE
[
				      
				        Director,  
				      
				      
				      
				      
				      ]







Type
Title
Conv/Exer price
Trans. date
Deemed Exe date
Trans Form Type
Trans Code
Eqty swap?
Footnote id
Trans timelines
# Shares
Value
Total Value
Price / share
Acq or Disp
Date exercisable
Expiration date
# Owned post trans
Value Owned post trans
Underlying security title
# Underlying securities
Value underlying securities
Direct or Indirect own
Nature indirect own

Derriv. transNon-Qualified Stock Options (Right to Buy)6.732007-05-304A : Grant / awardFalse66670A2017-05-306667Common stock $0.001 par value6667D












Filing date
2007-02-06
Submission
 0000932903-07-000006.nc

Form
3  Ownership: Initial statement of beneficial ownership of securities. Insider trading ( Directors, Officers, Significant Shareholders )
Issuer
 AVIGEN INC \DE  AVGN

Reporting Owner
 DILLY STEPHEN GEORGE
[
				      
				        Director,  
				      
				      
				      
				      
				      ]







Type
Title
Conv/Exer price
Trans. date
Deemed Exe date
Trans Form Type
Trans Code
Eqty swap?
Footnote id
Trans timelines
# Shares
Value
Total Value
Price / share
Acq or Disp
Date exercisable
Expiration date
# Owned post trans
Value Owned post trans
Underlying security title
# Underlying securities
Value underlying securities
Direct or Indirect own
Nature indirect own













Filing date
2007-02-06
Submission
 0000932903-07-000008.nc

Form
4  Ownership: Statement of changes in beneficial ownership. Insider trading ( Directors, Officers, Significant Shareholders )
Issuer
 AVIGEN INC \DE  AVGN

Reporting Owner
 DILLY STEPHEN GEORGE
[
				      
				        Director,  
				      
				      
				      
				      
				      ]







Type
Title
Conv/Exer price
Trans. date
Deemed Exe date
Trans Form Type
Trans Code
Eqty swap?
Footnote id
Trans timelines
# Shares
Value
Total Value
Price / share
Acq or Disp
Date exercisable
Expiration date
# Owned post trans
Value Owned post trans
Underlying security title
# Underlying securities
Value underlying securities
Direct or Indirect own
Nature indirect own

Derriv. transNon-Qualified Stock Options (Right to Buy)6.042007-02-054A : Grant / awardFalse300000A2017-02-0530000Common stock $0.001 par value30000D









←


 1 


→


 







db
 
 











































DILLY STEPHEN GEORGE Top Holdings  

































WhaleWisdom









Search All
Search 13F Filers Only
Search SEC Filer
Search Stocks Only
Search Mgmt Inv. Cos Only
ETFs Only
Search Active




















                      DILLY STEPHEN GEORGE
                    

•   ALAMEDA, CA
                      
How do I update this listing?




                                             Dilly Stephen George is based out of Alameda.    WhaleWisdom has at least 1 insider transactions (Form 3,4,5) in our database for Dilly Stephen George. 
                                           














Summary
13D/G
Insider (Form 4)



   Create Email Alert
 




×
Email Notification.







                   ***Log In or
                   Sign-up
                   to see more advanced email alert options such as selecting any type of
                   SEC form, multiple filers or classes of filers, and much more.***
                 

                    ...or to simply have an email sent to you whenever we receive a new
                           13F filing from DILLY STEPHEN GEORGE, enter your
                    email address below and choose 'Submit'.
                

Your email:








Cancel














Contact Info




dilly stephen george


C/O AVIGEN, INC.

ALAMEDA
CA
                                                        
                                                    94502


                                                      Business Phone:
                                                      5109706000
SEC SIC CODE:2836-BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)







Recent SEC Filings




4 filed on 06/27/2017
4 filed on 06/07/2017
4 filed on 05/12/2017
4 filed on 02/24/2017
4 filed on 11/15/2016
4 filed on 06/15/2016
4 filed on 02/26/2016
3 filed on 08/05/2015
4 filed on 06/24/2015
4 filed on 04/23/2014
















Schedule 13D and 13G events since 03/31/2017

Subscription required



 
Form 4 - Non-derivative Insider Transactions Since 03/31/2017
Loading...








Elevate your investments
Try it for free



















Genentech: Press Releases | Genentech Appoints Dilly Vice President of Medical Affairs









































Search





Contact Us





About Us












For Scientists


For Medical Professionals


For Patients


For Media


For Good


Now Hiring







Media /
                Press Releases












Attention: This page may not render properly. The browser you are using, Internet Explorer 10, is no longer supported.











Media Inquiries
(650) 467-6800








                        Print
                    








Media /
                Press Releases


Thursday, Dec 10, 1998
Genentech Appoints Dilly Vice President of Medical Affairs
 South San Francisco, Calif. -- December 10, 1998 --                     Genentech,
Inc.  (NYSE:GNE) today announced the appointment of Stephen George
Dilly, M.D., Ph.D., to vice president, Medical Affairs.  He will
report to Susan Hellmann, M.D., M.P.H., senior vice president
of Development and chief medical officer.  Dilly is responsible
for Genentech's Medical Affairs organization which includes the
clinical research and safety, data management/biostatistics, medical
information and product experience departments. 
 "Stephen brings a wealth of experience and enthusiasm to
this key position," said Hellmann.  "With his broad
experience and strong leadership, I am confident that he will
help maximize the clinical potential of our product candidates."
 Dilly, 39, has held various positions with SmithKline Beecham
Pharmaceuticals since 1988.  In 1996, he was named the director
and vice president of the Neurosciences Therapeutic Unit.  Before
that, he was director and vice president of the Cardiopulmonary
Therapeutic Team, group director of the Department of Clinical
Investigation, group director for Clinical Research & Development
in North America, director of the Department of Clinical Investigation
and senior medical adviser of the Headquarters Medical Department.
 Prior to his work at SmithKline Beecham, Dilly was the clinical
project manager of Central Research with Pfizer Inc. and research
fellow, Department of Physiology at Charing Cross Hospital Medical
School, London.
Dilly holds a doctorate in cardiac
physiology and a medical degree from the University of
London.
Genentech, Inc. is a leading biotechnology company that discovers,
develops, manufactures and markets human pharmaceuticals for significant
unmet medical needs.  Twelve of the currently marketed biotechnology
products stem from Genentech science.  Genentech markets seven
products directly in the United States.  The company has headquarters
in South San Francisco, California and is traded on the New York
Stock Exchange and Pacific Exchange under the symbol GNE.
# # #







Our Pipeline

Our pipeline includes new molecular entities that address serious unmet medical needs.




Approvals Timeline

A look at our approvals past and present.















 Feedback?
                    

Tell us what you think about our company, products, or website.


“

                    The scientist is not a person who gives the right answers, he’s one who asks the right questions.
                
”
– Claude Lévi-Strauss











Connect with us









































SGMO Stephen George Dilly Insider Trades for Sangamo Therapeutics Inc.


































Bulletin






Investor Alert







New York Markets Open in:



Market Snapshot
Analyst Ratings


















Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close































Sangamo Therapeutics Inc.

                  NASDAQ: SGMO
          



GO



Set Alerts
Find a Broker




Join TD Ameritrade




Market Index


 

Overview
      
Profile
      
News
      
Charts
      
Financials
      
Historical Quotes
      
Analyst Estimates
      
Options
      
SEC Filings
      
Insiders
      


/marketstate/country/us

Sangamo Therapeutics Inc.



After Hours
 --Quotes are delayed by 20 min
Jul 27, 2017, 5:55 p.m.


SGMO

/quotes/zigman/82231/composite


$
8.70




Change

-0.10
-1.14%

Volume
Volume 8,770
Quotes are delayed by 20 min








/quotes/zigman/82231/composite
Previous close

$
			9.35
		


$
				8.80
			
Change

-0.55
-5.88%





Day low
Day high
$8.35
$9.35










52 week low
52 week high

            $2.65
        

            $10.50
        


















Insider Activity


Individual




Stephen George Dilly



Dr. Stephen G. Dilly is President, Chief Executive Officer & Director at Aimmune Therapeutics, Inc. and Independent Director at Sangamo BioSciences, Inc. He is on the Board of Directors at Aimmune Therapeutics, Inc. and Sangamo BioSciences, Inc.
Dr. Dilly was previously employed as President, Chief Executive Officer & Director by PhotoThera, Inc., President & Chief Executive Officer by APT Pharmaceuticals, Inc., Chief Medical Officer & Senior Vice President by CHIRON Biopharmaceuticals, VP-Development Sciences & Medical Affairs by Genentech, Inc., and an Advisor by Physic Ventures LLC. He also served on the board at Avigen, Inc.
He received his doctorate degree from the University of London and a doctorate degree from the University of London.



Transactions


Date
Shares
Transaction
Value








        Copyright 2017 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
    











            Officers and Executives
        





Mr. Edward O. Lanphier 
Non-Executive Chairman




Dr. Alexander  Macrae 
President, Chief Executive Officer & Director




Ms. Kathy  Yi 
Chief Financial Officer & Senior Vice President




Dr. Michael  Holmes 
Vice President-Research




Dr. Edward R. Conner 
Chief Medical Officer & Senior Vice President




Dr. Dale G. Ando 
Chief Medical Officer & VP-Therapeutic Development




Dr. Mohammad A. El-Kalay 
Vice President-Technical Operations




Dr. Edward J. Rebar 
Vice President-Technology




Mr. Curt  Herberts 
Chief Business Officer & Senior Vice President




Mr. Joseph S. Zakrzewski 
Director




Dr. Roger A. Jeffs 
Director




Mr. Robert F. Carey 
Director




Mr. Bill R. Ringo 
Director




Mr. McDavid  Stilwell 
Vice President-Communications & Investor Relations




Ms. Heather  Erickson 
Chief of Staff




Ms. Shirley M. Clift 
Vice President-Regulatory Affairs




Ms. H. Stewart Parker 
Independent Director




Ms. Saira  Ramasastry 
Independent Director




Dr. Stephen George Dilly 
Independent Director




Dr. Steven J. Mento 
Independent Director









Trending Tickers


/quotes/zigman/17636479/composite VUZI+15.60%


/quotes/zigman/237947/composite JCP-5.83%


/quotes/zigman/59392505/composite NUGT-2.93%


/quotes/zigman/59386294/composite JNUG-5.94%


/quotes/zigman/65801738/composite TLT+1.11%


X




Powered by














Log In




7:47 AM EDT
July 28, 2017


/marketstate/country/us
New York

	Pre


/marketstate/country/uk
London

	Open


/marketstate/country/jp
Tokyo

	Closed





/marketstate/country/us
 


/marketstate/country/uk
 


/marketstate/country/jp
 











View All



Latest News

/news/latest
7:46aAbbVie shares up 1.8% in premarket trade
7:46aAbbVie still sees full-year adj. EPS $5.44 to $5.54
7:46aAbbVie still sees full-year EPS $4.55 to $4.65
7:45aAbbVie Q2 revenue $6.94 bln vs. $6.45 bln; FactSet consensus $6.93 bln
7:44aAbbVie Q2 adj. EPS $1.42; FactSet consensus $1.40
7:44aGoodyear's stock plunges 9.1% premarket after Q2 results
7:44aAbbVie Q2 EPS $1.19 vs. 98 cents
7:44aGoodyear cuts 2017 segment operating income outlook to $1.60 bln-$1.65 bln from $2.0 bln
7:43aGet ready for the less-profitable Amazon that you used to know 
7:42aWells Fargo charged customers for duplicate car insurance
7:42aGoodyear Q2 sales $3.69 bln vs. $3.88 bln; FactSet consensus $3.73 bln
7:42aCORRECT: Goodyear Q2 adj. EPS 70 cents; FactSet consensus 70 cents
7:40aGoodyear Tire & Rubber Q2 EPS 58 cents vs. 75 cents a year ago
7:40aAmerican Air shares jump 3% after profit beat
7:37aAmerican Airlines's stock jumps 2.9% premarket after Q2 results
7:37aAmerican Airlines to invest $4.1 bln in new aircraft in 2017
7:36aAmerican Airlines Q2 passenger load factor 83.7% vs. 82.9% a year ago
7:35aAmerican Airlines Q2 PRASM up 6.0%
7:34aAmerican Airlines Q2 mainline passenger revenue up 7.5% to $7.75 bln
7:33aAmerican Airlines Q2 $11.11 bln vs. $10.36 bln; FactSet consensus $11.06 bln
Loading more headlines...




dow

/quotes/zigman/627449/realtime
21,796.55

+85.54
+0.39%





nasdaq

/quotes/zigman/12633936/realtime
6,382.19

-40.56
-0.63%





s&p 500

/quotes/zigman/3870025/realtime
2,475.42

-2.41
-0.10%













Kiosk


1352872800000
1352872800000


The RetireMentors






				Retirement advice from our industry experts
				Our team of financial professionals can help you plan and save 
					for retirement, then 
				live well in it.



/conga/kiosk/retirementors.html
361307




1320411600000
1320616500000


Alerts



/conga/kiosk/alerts.html
310238




1333717800000
1333964100000


Virtual Stock Exchange





Our free stock-market game
				• Trade your virtual portfolio in real time
				• Talk strategies in group discussions
				• Find or create a game that suits you
				• Use our learning center to improve 



/conga/kiosk/games.html
310284




1245657600000
1277280000000


Location Scouts




Housing-market insights from our realty pros
																																																							Plus the latest data from Realtor.com on 21 home markets across the U.S.
• See our complete Real Estate site


/conga/kiosk/real_estate.html
357012




1404799200000
1404799200000


Lazy Portfolios





				Set it and forget it
				Check out the returns on our 8 Lazy Portfolios that are made up 
				of low-cost 
				buy-and-hold index funds.

				• How to create your own Lazy Portfolio


/conga/kiosk/lazy_portfolio.html
313134














MarketWatch.com




Site Index
Topics
Help
Feedback
Newsroom Roster

                    Media Archive
Premium Products
Mobile


Company Info
Code of Conduct
Corrections
Advertising Media Kit
Advertise Locally
Reprints & Licensing
Broker Center

                    Your Ad Choices


Follow MarketWatch


































RSS
Podcasts






WSJ.com
Barron's Online
BigCharts
Virtual Stock Exchange


Financial News London
WSJ.com Small Business
realtor.com
Mansion Global












		Copyright © 2017 MarketWatch, Inc.  All rights reserved.
		By using this site, you agree to the Terms of Service,
        Privacy Policy and Cookie Policy.
	



            Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
        






MarketWatch Top Stories
Link to MarketWatch's Slice.

15






















































